Indian drugmaker Hikma has agreed in principle to a $150 million settlement to resolve lawsuits claiming that it contributed to the opioid crisis in the US, which could allow it to put the ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Drugmaker Hikma is in talks with partners across the world to prepare to sell a generic version of Ozempic ...

Hikma is introducing mercaptopurine oral suspension, in a 20mg/ml dose, which is the first generic of this product. Hikma was the first approved applicant with a Competitive Generic Therapy ...

Healthcare & Pharmaceuticalscategory· December 23, 2024 US FDA approves Hikma's generic version of Novo's diabetes drug Victoza The U.S. Food and Drug Administration on Monday approved Hikma ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...

Axsome Therapeutics has entered into a settlement agreement with Hikma resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the ...

In a report released today, James Gordon from J.P. Morgan reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report). The ...